Scarica l'app Stockscreener
10.72
0.09%
0.010
Dopo l'orario di chiusura:
10.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.71
Aprire:
$10.68
Volume 24 ore:
90,129
Relative Volume:
0.78
Capitalizzazione di mercato:
$375.92M
Reddito:
$51.00M
Utile/perdita netta:
$-8.73M
Rapporto P/E:
-36.19
EPS:
-0.2962
Flusso di cassa netto:
$-7.75M
1 W Prestazione:
+0.94%
1M Prestazione:
-2.19%
6M Prestazione:
+84.51%
1 anno Prestazione:
+25.09%
Intervallo 1D:
$10.42
$10.83
Intervallo di 1 settimana:
$10.08
$10.86
Portata 52W:
$5.65
$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Nome
Fennec Pharmaceuticals Inc
Settore
Industria
Telefono
(919) 636-4530
Indirizzo
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
10.72 | 375.92M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Iniziato | B. Riley Securities | Buy |
| 2026-01-09 | Iniziato | Piper Sandler | Overweight |
| 2022-11-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Iniziato | CapitalOne | Overweight |
| 2022-08-08 | Ripresa | Craig Hallum | Buy |
| 2020-06-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Iniziato | Goldman | Buy |
Mostra tutto
Fennec Pharmaceuticals Inc Borsa (FENC) Ultime notizie
TRex Bio Files for Nasdaq IPO - Yahoo! Finance Canada
Award shares leave restriction as Fennec Pharmaceuticals (FENC) CFO acquires 1,703 shares. - stocktitan.net
Medical chief acquires 168 awarded shares at Fennec Pharmaceuticals (FENC), holding 9,687 directly. - stocktitan.net
Commercial chief acquires 168 shares released from restriction at Fennec Pharmaceuticals (FENC). - stocktitan.net
1,159 award shares released; Fennec Pharmaceuticals (FENC) CEO directly holds 67,461 shares afterward. - stocktitan.net
After a 156-share award release, Fennec (FENC) strategy chief holds 24,800 shares. - stocktitan.net
FENC 8-K FilingsFennec Pharmaceuticals Inc. SEC 8-K - stocktitan.net
Fennec Pharmaceuticals (FENC) director exercises options, then sells matching shares - Stock Titan
Director at Fennec Pharmaceuticals (NASDAQ: FENC) plans to sell 15,545 shares - Stock Titan
Fennec Pharmaceuticals (NasdaqCM:FENC) Stock Forecast & Analyst Predictions - Simply Wall Street
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
Fennec Pharmaceuticals Stock Price Forecast. Should You Buy FRX.TO? - StockInvest.us
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Insider Rosty Raykov Reports Share Vesting and Sale - kalkinemedia.com
Former Fennec (NASDAQ: FENC) director lines up $121K stock sale - Stock Titan
Former Fennec Pharma (NASDAQ: FENC) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fennec CCO receives 168 shares at zero cost - Stock Titan
Fennec Pharma CEO gains 1,159-share award - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 12,000 shares - Stock Titan
156 previously restricted Fennec Pharma (FENC) shares are released to the chief strategy officer at a stated $0.00 per share. - Stock Titan
Fennec (NASDAQ: FENC) CMO sells 12,000 vested shares in an August 31 trade not tied to a preset Rule 10b5-1 plan. - Stock Titan
CFO boosts stake at Fennec Pharmaceuticals (FENC) as 1,703 previously restricted shares are released to him - Stock Titan
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - webull.com
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - simplywall.st
Fennec Pharma (NASDAQ: FENC) CFO sells 75K shares in plan trade - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 75,000 shares - Stock Titan
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:FENC - TradingView
Fennec (FENC) Results Review: Reported EPS Tops Expectations in the Latest Reading; Share Response: The Share Price Sheds 4.63% at the CloseEPS Estimate Trend - vinanet.vn
Fennec (FENC) Results Check: Profit Per Share Clears Its Benchmark on the Day; Investor Response - vinanet.vn
Fennec (FENC) Technical Check: Adds 0.51% to Close at $11.89 at the Close; Current Setup: the Supplied Trading Band Runs From $11.30 to $12.48Throwback Trade - vinanet.vn
Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals - hrtoday.in
(FENC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Maxim Group - The Globe and Mail
Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake - Stock Titan
Results: Fennec Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
Fennec Pharmaceuticals Announces Q2 2026 Net Income and Revenue Growth - Kalkine Media
Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question - webull.com
Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush - The Globe and Mail
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC) - MarketBeat
Wedbush Boosts Adherex Technologies (NASDAQ:FENC) Price Target to $16.00 - MarketBeat
Fennec Pharmaceuticals Inc Azioni (FENC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fennec Pharmaceuticals Inc Azioni (FENC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MARCO BRUGHERA | Director |
Sep 15 '26 |
Proposed Sale |
10.30 |
15,545 |
160,070 |
0 |
| Brughera Marco Maria | Director |
Sep 15 '26 |
Sale |
10.29 |
15,545 |
159,958 |
0 |
| ROSTISLAV RAYKOV | Former Director |
Sep 01 '26 |
Proposed Sale |
12.12 |
10,000 |
121,177 |
0 |
| Raykov Rosty | Former Director |
Sep 01 '26 |
Sale |
12.11 |
10,000 |
121,100 |
124,411 |
| PIERRE S SAYAD | Officer |
Aug 31 '26 |
Proposed Sale |
12.18 |
12,000 |
146,170 |
0 |
| Sayad Pierre Sargis | Chief Medical Officer |
Aug 31 '26 |
Sale |
12.18 |
12,000 |
146,160 |
9,519 |
| Andrade Robert | CHIEF FINANCIAL OFFICER |
Aug 28 '26 |
Option Exercise |
5.10 |
21,928 |
111,833 |
239,603 |
| ROBERT ANDRADE | Officer |
Aug 27 '26 |
Proposed Sale |
11.79 |
75,000 |
883,898 |
0 |
| Andrade Robert | CHIEF FINANCIAL OFFICER |
Aug 27 '26 |
Sale |
11.78 |
75,000 |
883,500 |
217,675 |
| ROSTISLAV RAYKOV | Former Director |
Aug 03 '26 |
Proposed Sale |
9.58 |
10,000 |
95,835 |
0 |
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):